Source Title: Sprint! Five New Coronavirus Vaccines in China Undergo Phase III Clinical Trials
Xinhua News Agency, Beijing, December 16, “China has five new coronavirus vaccines currently in clinical trial phase III, and the number is among the highest in the world.” Joint Prevention and Control Mechanism of the State Council Scientific Research Group Vaccine Research and Development Team Leader, National Healthcare In an exclusive interview with Xinhua News Agency, Zheng Zhongwei, Director of the Research Center for Medicine and Science and Health Technology Committee, said: “Vaccine research and development has entered the sprint stage.
Zheng Zhongwei said that evaluating a vaccine requires multiple comprehensive indicators, of which safety, efficacy, accessibility and affordability are the most important. “We are ready for mass production.”
It is understood that since the outbreak, the investigation team of the Joint Prevention and Control Mechanism of the State Council for Vaccine Research and Development and related parties have promoted all aspects of vaccine work in a state of war, and scientific researchers have raced against the clock and worked hard to address the problem. Currently, 15 vaccines in 5 technical pathways have entered clinical trials.
Relevant parties continue to scientifically and rigorously advance phase III clinical trials of the vaccine, and do a good job of review and approval in strict compliance with internationally recognized laws, regulations, and technical standards to ensure that the vaccine is safe and effective. It can withstand all inspections and can withstand historical inspections.
Vaccines that have entered phase III clinical trials include two inactivated vaccines from Sinopharm Sinopharm, an inactivated vaccine from Beijing Kexing Zhongwei Company, an adenovirus vector vaccine jointly developed by the Military Medical Research Institute and Kangsino Company, Chinese Academy of Sciences A recombinant protein vaccine jointly developed by the Institute for Microbiology and Zhifei Biological Company.
Since the new corona pneumonia epidemic has been effectively controlled in China, the country no longer has the conditions to conduct phase III clinical trials. Therefore, the previous phase III clinical trials are mainly conducted abroad, and they also face some difficulties and challenges.
Faced with the new situation and new problems facing the new epidemic of corona pneumonia that has occurred once in a century, more innovative thinking and more responsibilities are required.
According to the news previously announced by the Joint Prevention and Control Mechanism of the State Council, China has started emergency use of the new coronavirus vaccine in June. (Reporters Chen Fang and Dong Ruifeng)
Xinhua News Agency, Beijing, December 16, “China has five new coronavirus vaccines that are currently in phase III clinical trials, the number is among the highest in the world.” In an exclusive interview with Xinhua News Agency, Zheng Zhongwei, director of the Committee’s Center for Research on Medicine and Health Science and Technology, said: “Vaccine research and development has entered the sprint stage.
Zheng Zhongwei said that evaluating a vaccine requires multiple comprehensive indicators, of which safety, efficacy, accessibility and affordability are the most important. “We are ready for mass production.”
It is understood that since the outbreak, the investigation team of the Joint Prevention and Control Mechanism of the State Council for Vaccine Research and Development and related parties have promoted all aspects of vaccine work in a state of war, and scientific researchers have raced against the clock and worked hard to address the problem. Currently, 15 vaccines in 5 technical pathways have entered clinical trials.
Relevant parties continue to scientifically and rigorously advance phase III clinical trials of the vaccine, and do a good job of review and approval in strict compliance with internationally recognized laws, regulations, and technical standards to ensure that the vaccine is safe and effective. It can withstand all inspections and can withstand historical inspections.
Vaccines that have entered phase III clinical trials include two inactivated vaccines from Sinopharm Sinopharm, an inactivated vaccine from Beijing Kexing Zhongwei Company, an adenovirus vector vaccine jointly developed by the Military Medical Research Institute and Kangsino Company, Chinese Academy of Sciences A recombinant protein vaccine jointly developed by the Institute for Microbiology and Zhifei Biological Company.
Since the new corona pneumonia epidemic has been effectively controlled in China, the national conditions for phase III clinical trials are no longer available. Therefore, the aforementioned phase III clinical trials are mainly conducted abroad and also face some difficulties and challenges.
Faced with the new situation and new problems facing the new epidemic of corona pneumonia that has occurred once in a century, more innovative thinking and more responsibilities are required.
According to the news previously announced by the Joint Prevention and Control Mechanism of the State Council, China has started emergency use of the new coronavirus vaccine in June. (Reporters Chen Fang and Dong Ruifeng)
